Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study-Reference-Cited by-同舟云学术

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study

Published:2015-09 Issue:9 Volume:16 Page:1133-1142
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Reid Tony,Oronsky Bryan,Scicinski Jan,Scribner Curt L,Knox Susan J,Ning Shoucheng,Peehl Donna M,Korn Ron,Stirn Meaghan,Carter Corey A,Oronsky Arnold,Taylor Michael J,Fitch William L,Cabrales Pedro,Kim Michelle M,Burris Howard A,Lao Christopher D,Abrouk Nacer E D,Fanger Gary R,Infante Jeffrey R

Publisher

Elsevier BV

Subject

Oncology

Reference39 articles.

1. Evolution of acquired resistance to anti-cancer therapy;Foo;J Theor Biol,2014

2. Gene silencing in cancer in association with promoter hypermethylation;Herman;N Engl J Med,2003

3. Cabrales P, Reid T, Oronsky B et al. RRx-001 an EXO-based epigenetic anti-cancer agent in phase 2 clinical trials. ISEV2014 Educational Event; San Diego, CA, USA; Oct 26, 2014.

4. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials;Ning;Cancer Res,2012

5. Anti-myeloma activity of a novel free radical inducer RRx-001;Sharma Das;Blood,2014

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemical Strategies Toward Prodrugs and Fluorescent Probes for Gasotransmitters;Mini-Reviews in Medicinal Chemistry;2024-02

2. Data Management 101 for drug developers: A peek behind the curtain;Clinical and Translational Science;2023-07-06

3. PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy;International Journal of Radiation Oncology*Biology*Physics;2023-07

4. RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist;Frontiers in Oncology;2023-05-29

5. Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME);Frontiers in Immunology;2023-03-07